Genetech announced results from CLL11, a Phase 3 study of obinutuzumab (GA101), comparing the combination of either obinutuzumab or Rituxan and chlorambucil to chlorambucil alone in chronic lymphocytic leukemia (CLL).
Gilead announced Phase 2 results for idelalisib, an oral inhibitor of PI3K delta in combination with rituximab for older patients with treatment-naïve chronic lymphocytic leukemia.
The FDA has accepted Seattle Genetics' sBLA for filing of Adcetris for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Leukemia experts call for examination of the 'right' way to price life-saving drugs
For patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia, activating mutations in the gene encoding the colony stimulating factor 3 receptor are common.
A monoclonal antibody has been found to be cytotoxic to chronic lymphocytic leukemia B cells while having little effect on normal B cells.
Chronic fatigue is more than three times more prevalent among adult survivors of childhood leukemia or lymphoma than among other adults.
Treatment with autologous engineered T cells is effective bridge to potentially curative therapy
Inhibiting the protein receptor Mer destroys cancer cells and enhances chemotherapy in both acute myeloid and acute lymphoblastic leukemia.
Specially treated T cells infused into high-risk and relapsed leukemia patients can prolong survival after stem cell transplantation.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|